Sign in

CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Definium Therapeutics, Inc.

Sign in to watch
Ticker
DFTX
Exchange
Nasdaq
Industry
Medicinal Chemicals & Botanical Products
FY end
Dec 31
Incorporated
British Columbia, Canada
Entity type
operating
Phone
212-220-6633
Business address
ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
Former names
Mind Medicine (MindMed) Inc.
  1. 3 Insider Initial Statement of Ownership
  2. 3 Insider Initial Statement of Ownership
  3. 4 Open-market sale Chief Medical Officer sold 18,217 shares at $0.69 ($12,570)
  4. 4 Open-market sale Chief Executive Officer sold 18,681 shares at $0.69 ($12,890)
  5. 4 Open-market sale Chief Executive Officer sold 19,388 shares at $0.70 ($13,572)
  6. 4 Open-market sale Chief Executive Officer sold 36,762 shares at $0.70 ($25,733)
  7. 4 Open-market sale Chief Medical Officer sold 26,238 shares at $0.70 ($18,367)
  8. 4 Open-market sale Chief Executive Officer sold 21,275 shares at $0.70 ($14,893)
  9. 4/A Grant or award Director acquired 64,656 shares (grant or award)
  10. 4/A Grant or award Director acquired 43,104 shares (grant or award)
  11. 4/A Grant or award Director acquired 21,552 shares (grant or award)
  12. 4 Grant or award Director acquired 43,104 shares (grant or award)
  13. 4 Grant or award Director acquired 64,656 shares (grant or award)
  14. 4 Grant or award Director acquired 21,552 shares (grant or award)
  15. 4/A Grant or award Chief Financial Officer acquired 1,270,000 shares (grant or award)
  16. 4 Open-market sale Chief Medical Officer sold 9,555 shares at $0.82 ($7,835)
  17. 4 Open-market sale Chief Executive Officer sold 18,415 shares at $0.77 ($14,180)
  18. 4 Open-market sale Chief Medical Officer sold 8,242 shares at $0.77 ($6,346)
  19. 4 Other acquisition Director acquired 67,678 shares (other)
  20. 4 Grant or award Chief Financial Officer acquired 1,270,000 shares (grant or award)

Page 8 of 10 · 186 filings